Recently added

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

Eng, Cathy; Kim, Tae Won; Wasan, Harpreet; Kopetz, Scott; Yoshino, Takayuki; Van Cutsem, Eric; Tabernero, Josep (Nature Portfolio, 2025-03)

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Moehler, Markus; Lee, Keun-Wook; OH, DO-YOUN; Kato, Ken; Arkenau, Hendrik-Tobias; Tabernero, Josep (Adis, 2025-05)

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

de Jager, Vincent D.; Giacomini, Patrizio; Fairley, Jennifer A.; Patton, Simon; Joosse, Simon A.; Toledo, Rodrigo (Elsevier, 2025-04)

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

Thorne, Eleanor; O'Connor, Miriam; Elez, Elena; Hardy, Claire; KAMPOSIORAS, KONSTANTNOS; Punie, Kevin (Elsevier, 2025-03)

Identifying germline pathogenic variants in breast cancer using tumor sequencing

Papakonstantinou, Andri; Castillo, Ester; Vega Cano, Kreina Sharela; Torres López, Maite; Moles-Fernández, Alejandro; Cruellas , Mara; Lopez-Fernandez, Adrià; Matito, Judit; Gómez-Rey, Marina; Rezqallah Arón , María Alejandra; Saura Manich, Cristina; Vivancos, Ana; Balmaña, Judith; Oliveira, Mafalda; Navarro Garces, Victor (Elsevier, 2025-06)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

Identifying germline pathogenic variants in breast cancer using tumor sequencing

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial ﻿

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305 ﻿

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop ﻿

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series ﻿

Identifying germline pathogenic variants in breast cancer using tumor sequencing ﻿

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop

Oncology professionals' perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series

Identifying germline pathogenic variants in breast cancer using tumor sequencing